AptaTargets
VerifiedA clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$22—33m (Dealroom.co estimates Oct 2020.)
Company register number B87154118
Madrid Community of Madrid (HQ)
- hard tech
- biotechnology
- horizon europe
- woman founder
- biotech and pharma
- eit ecosystem
- neurology
- eit health
- eit supernovas
- eicfund
- headstart (eit health)
- immune system
- european health catapult (eit health)
- microbiology
- headstart 2018 (eit health)
- rna
- bridgehead europe (eit health)
- european health catapult 2018 (eit health)
- bridgehead europe 2019 (eit health)
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 204 % | 57 % | 2 % | (14 %) | 12 % | 20 % | 8 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 2 % | 13 % | 5 % | 13 % | 15 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | 6 % | (2 %) | 2 % | 1 % | - | - |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | $0.0 | round |
| investor | $0.0 | round | |
| investor | $0.0 | round | |
| investor | $0.0 | round | |
| investor investor | $0.0 | round | |
| investor | $0.0 | round | |
* | N/A | Early VC | |
| Total Funding | 000k | ||
Related Content
Recent News about AptaTargets
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.